Intestinal mucosa nerve ending

Intestinal mucosa nerve endings represent the terminal projections of both intrinsic enteric neurons (primarily from the submucosal plexus) and extrinsic primary afferent neurons (vagal and spinal) that innervate the mucosal layer of the gastrointestinal tract [1, 2]. These structures are not a single molecular target but rather an anatomical site containing a diverse array of receptors and ion channels, such as 5-HT3 receptors, mu-opioid receptors, and voltage-gated sodium channels [3, 5]. Their primary biological function is to sense luminal stimuli—including mechanical distension, chemical composition, and inflammatory signals—and translate these into electrical signals that regulate local secretion, blood flow, and the sensation of pain or discomfort [2, 4]. In clinical practice, these nerve endings are the site of action for various pharmacological agents used to treat gastrointestinal disorders like irritable bowel syndrome (IBS) and chronic diarrhea, where they often exhibit hypersensitivity or structural remodeling [3, 6]. Because they integrate multiple signaling pathways, targeting the receptors located on these endings allows for the modulation of visceral sensitivity and secretomotor functions [7, 8]. Understanding the neurobiology of these mucosal endings is crucial for developing treatments for functional gastrointestinal disorders [6].

Other names

Mucosal nerve terminalsEnteric mucosal afferentsSubmucosal plexus nerve endingsIntestinal sensory nerve endings

Pharmacological agents modulate these structures by targeting specific receptors (e.g., 5-HT3, 5-HT4, mu-opioid) or ion channels (e.g., NaV1.7, NaV1.8) located on the nerve terminals to alter neurotransmitter release or action potential propagation.